News

Net earnings for the first quarter of 2008 increased 24% to $429.4 million, or $1.43 per share on a diluted basis, compared to $346.2 million, or $1.14 per

The financing was obtained from existing investors, including Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and the Aurora Funds. The company plans to use the proceeds raised in this

The assay is performed on a Luminex cytometer using a multi-probe liquid bead array method. The liquid bead array format provides comprehensive information in a single well, providing

The plan allows Ark to develop Cerepro for operable high grade glioma in children from one month up to 18 years old. The paediatric work will not commence

This approval is claimed to be a significant milestone in the company’s continued worldwide expansion. Surgeons in China will now have access to the company’s full line of

The Deep study was designed to investigate whether treatment with a Digoxin Immune Fab (DIF) Digibind, (GlaxoSmithKline) could influence the progression of the disease by neutralizing endogenous digoxin-like

The three-year agreement, with effect from June 1, 2008, will help to introduce Medihoney Wound & Burn Dressing with active leptospermum honey to the organization’s growing customer base,

This US Phase IIb Betas trial is similar to the previously announced Canadian-based Regenesis trial. The recruitment target for this US study is to enroll 20-30 patients at

The study has used a mouse model that spontaneously forms breast cancer. These tumors develop and spread to the lungs at known developmental time points. Such models are